Cushing's Syndrome and Cushing Disease: Treatment Value Begins with the Correct Diagnosis

Executive Perspective

For organizations investing in Cushing's syndrome, commercial planning typically focuses on clinical differentiation, market access, pricing, physician adoption, and competitive positioning.

These are all critical components of a successful launch.

However, they all depend on one event that occurs much earlier.

Unlike many therapeutic areas where multiple therapies compete for a well-defined patient population, Cushing's syndrome presents a different commercial challenge. The greatest barrier to commercial success is often not competition—it is identifying patients early enough to enter the treatment pathway.

Today, relatively few therapies compete in this market. Yet thousands of patients are estimated to live with endogenous hypercortisolism, while many remain undiagnosed or experience years of delay before reaching an endocrinologist with expertise in Cushing's syndrome.

For commercial organizations, understanding the diagnostic journey may be just as important as understanding the competitive landscape.

The Commercial Opportunity Is Smaller Than Epidemiology Suggests

Biotechnology companies frequently begin commercial planning with prevalence estimates.

While epidemiology establishes the potential disease burden, it does not define the commercially addressable market.

Every patient must successfully progress through a series of clinical and healthcare system transitions before treatment can begin.

The Commercial Patient Journey

At each step, patients are lost.

Some are never recognized.

Others are diagnosed only after years of progressive disease.

Some never reach physicians experienced in managing complex hypercortisolism.

Diagnosis Is the First Commercial Barrier

Most patients with Cushing's syndrome do not initially present to an endocrinologist.

Instead, they enter the healthcare system through primary care or other medical specialties with conditions that appear unrelated:

• Resistant hypertension
• Type 2 diabetes
• Progressive central obesity
• Osteoporosis
• Depression or anxiety
• Proximal muscle weakness
• Easy bruising
• Adrenal incidentalomas

Each condition is appropriately managed in isolation.

The underlying endocrine disorder often remains unrecognized.

This creates the first—and perhaps the most significant—commercial barrier.

Cushing's Syndrome and Cushing Disease Follow Different Clinical Pathways

Commercial planning also requires an appreciation for the distinction between Cushing's syndrome and Cushing disease.

Cushing's syndrome describes hypercortisolism regardless of cause.

Cushing disease specifically results from an ACTH-secreting pituitary adenoma.

Although related, these conditions differ in diagnostic evaluation, referral patterns, surgical management, long-term follow-up, and the specialists who ultimately influence treatment decisions.

Organizations that understand these referral pathways can develop more focused Medical Affairs strategies, physician education initiatives, and commercial engagement plans.

Medical Affairs Has an Opportunity Before Launch

The endocrine community already has well-established diagnostic tools and evidence-based clinical guidelines.

The challenge is rarely the availability of diagnostic testing.

The challenge is recognizing the appropriate patient early enough to begin that evaluation.

This creates an opportunity for Medical Affairs long before commercialization begins.

Scientific exchange, disease-state education, collaboration with endocrine Centers of Excellence, and evidence-based physician education can help shorten the time between symptom onset and referral.

These initiatives should not be viewed simply as launch preparation.

Questions Every Commercial Team Should Ask

Organizations investing in Cushing's syndrome should consider several strategic questions early in development:

• Is our commercial forecast based on disease prevalence or diagnosed patients?
• Where do patients experience the greatest delays in diagnosis?
• Which physician specialties most often recognize—or overlook—the disease?
• Which endocrine Centers of Excellence establish future standards of care?
• How will Medical Affairs support earlier disease recognition through scientific education?
• What evidence will payers require to support reimbursement?
• Which barriers can realistically be reduced before launch?

These questions influence commercial performance years before the first sales representative is hired.

Why This Matters to Investors and Commercial Leaders

Commercial forecasts often assume that diagnosed patients will naturally enter the treatment pathway.

In reality, diagnosis, referral, specialist access, reimbursement, and long-term treatment each introduce friction that reduces the commercially addressable population.

Understanding these barriers produces more realistic revenue expectations, more effective resource allocation, and stronger launch planning.

Executive Insight

Many organizations invest substantial resources developing innovative therapies, generating clinical evidence, and preparing for launch. These investments are essential, but they cannot create value if patients never enter the treatment pathway.

In Cushing's syndrome, commercial success is influenced by far more than product differentiation. It depends on understanding where patients are lost throughout the diagnostic journey, how referral patterns influence specialist care, and which barriers delay treatment long before a prescribing decision is made.

Organizations that recognize these challenges early can build more realistic commercial forecasts, develop stronger Medical Affairs strategies, and focus investments where they have the greatest long-term impact.

The most successful companies will not simply compete for diagnosed patients—they will understand the healthcare system well enough to help more patients reach a diagnosis in the first place.